GlassScriptPhysician profile
Stephanie L Perry
NPI 1104842434
$18,523.71
in general payments reported to CMS, 2019-2025
54 companies · $2,835 in 2025
The $2,835 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,851 · 2020: $2,246 · 2021: $2,551 · 2022: $2,649 · 2023: $2,604 · 2024: $2,788 · 2025: $2,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,167 · Education: $59.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,167.48 |
| Education | $59.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,937.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,858.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,822.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,767.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,656.18 | 2019-2025 | |
| Amgen INC. | $1,409.21 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,307.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $969.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $463.83 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $399.32 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $305.81 | 2019-2025 | |
| Amarin Pharma, INC. | $301.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $301.07 | 2019-2025 | Eliquis, Camzyos |
| Kowa Pharmaceuticals America, INC. | $287.63 | 2020-2025 | Zoryve, Livalo |
| Astellas Pharma US INC | $270.57 | 2019-2025 | Veozah |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.